Our results revealed that CHRNA5 silencing could augment sorafenib sensitivity, and CHRNA5 overexpression could attenuate sorafenib sensitivity, indicating the regulatory role of CHRNA5 in sorafenib sensitivity in HCC. The gene discussed is CHRNA5; the disease is hepatocellular carcinoma.